BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 22, 2024
See today's BioWorld
Home
» Adolor Suffers Setback On FDA Request For More Entereg Data
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Adolor Suffers Setback On FDA Request For More Entereg Data
Nov. 7, 2006
By
Aaron Lorenzo
No Comments
The FDA delayed approving Adolor Corp.'s Entereg (alvimopan) for postoperative ileus yet again, pending additional safety data, causing the company's shares to tumble by 44.8 percent on Monday. (BioWorld Today)
BioWorld
